San Francisco, California, United States, November 2025 — Braveheart Bio has announced the appointment of Mark Henderson as the new Vice President, Manufacturing and CMC, further strengthening its technical leadership as the company advances its late-stage therapeutic pipeline. In this strategic position, Mark will support the organisation’s efforts in progressing novel treatments for hypertrophic cardiomyopathy and related conditions through robust Chemistry, Manufacturing and Controls (CMC) frameworks and world-class manufacturing systems.
Mark joins Braveheart Bio after serving as Vice President, Technical Operations at Neuvivo, Inc., where he spent more than a year overseeing technical leadership, regulatory interactions, CMC development, and operational execution across key technology platforms. His work contributed to strengthening Neuvivo’s development programs through strong cross-functional coordination and regulatory engagement.
Prior to Neuvivo, Mark held a significant four-year leadership role as Vice President, Manufacturing and Process Development at Dantari, Inc. He led GMP operations for the company’s polymer nanoparticle-based cancer programs, oversaw internal formulation and analytical teams, implemented GMP quality systems, managed global CDMO partnerships, and guided CMC programs for investigational oncology therapeutics entering clinical trials. He also served on Dantari’s Senior Leadership Team, working closely with functional heads across research, business operations, development, and clinical functions.
Mark’s most extensive experience comes from an exceptional 18-year tenure at BioMarin Pharmaceutical Inc., where he progressed through multiple senior roles including Executive Director, Contract Manufacturing; Senior Director, Drug Substance Contract Manufacturing; Director of Drug Substance Manufacturing; Principal Scientist; and QA leadership positions. His responsibilities spanned global CMO management, GMP drug substance and drug product operations, regulatory submissions, lifecycle management, specialty raw material production, synthetic chemistry programs, IND/NDA/BLA/MAA documentation, and participation in multifunctional leadership teams supporting discovery, development, and commercial operations.
Earlier in his career, Mark served at Genentech in South San Francisco, where he spent more than four years in leadership roles including Senior Manager and Senior Manager, Corporate EHS Programs, contributing to QA deviation assessments, technical evaluations, and EHS oversight within biologics manufacturing environments.
About Braveheart Bio
Braveheart Bio is a late clinical-stage biotechnology company focused on developing novel therapeutics for hypertrophic cardiomyopathy and related disorders. Supported by leading global life science investors — including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences — Braveheart Bio aims to set a new standard of care in cardiovascular health. The company is advancing its lead candidate BHB-1893 through late-stage clinical development, driven by a commitment to scientific rigor, patient-centric innovation, and breakthrough therapeutic potential.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
